Download PDF
Semin Respir Crit Care Med 2015; 36(01): 126-135
DOI: 10.1055/s-0034-1398390
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Colistin: How should It Be Dosed for the Critically Ill?

Cornelia B. Landersdorfer
1   Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
,
Roger L. Nation
1   Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
02 February 2015 (online)

   Permissions and Reprints

Abstract

Colistin, an “old” polymyxin antibiotic, is increasingly being used as last-line treatment against infections caused by multidrug-resistant gram-negative bacteria. It is administered in patients, parenterally or by inhalation, as its inactive prodrug colistin methanesulfonate (CMS). Scientifically based recommendations on how to optimally dose colistin in critically ill patients have become available over the last decade and are extremely important as colistin has a narrow therapeutic window. A dosing algorithm has been developed to achieve desired plasma colistin concentrations in critically ill patients. This includes the necessary dose adjustments for patients with impaired kidney function and those on renal replacement therapy. Due to the slow conversion of CMS to colistin, a loading dose is needed to generate effective concentrations within a reasonable time period. Therapeutic drug monitoring is warranted, where available; because of the observed high interpatient variability in plasma colistin concentrations. Combination therapy should be considered when the infecting pathogen has a colistin minimum inhibitory concentration above 1 mg/L, as increasing the dose may not be feasible due to the risk for nephrotoxicity. Inhalation of CMS achieves considerably higher colistin concentrations in lung fluids than is possible with intravenous administration, with negligible plasma exposure. Similarly, for central nervous system infections, dosing CMS directly into the cerebrospinal fluid generates significantly higher colistin concentrations at the infection site compared with what can be achieved with systemic administration. While questions remain to be addressed via ongoing research, this article reviews the significant advances that have been made toward optimizing the clinical use of colistin.

Keywords

colistin - critically ill - polymyxins - colistin methanesulfonate - pharmacokinetics - pharmacodynamics - toxicodynamics - optimized dosing
 

  • References

  • 1 Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72 (6) 857-868
    CrossrefPubMedSearch in Google Scholar
  • 2 Li J, Nation RL, Turnidge JD , et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6 (9) 589-601
    CrossrefPubMedSearch in Google Scholar
  • 3 Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol 2011; 11 (5) 464-469
    CrossrefPubMedSearch in Google Scholar
  • 4 Hede K. Antibiotic resistance: An infectious arms race. Nature 2014; 509 (7498) S2-S3
    CrossrefPubMedSearch in Google Scholar
  • 5 Roberts JA, Abdul-Aziz MH, Lipman J , et al; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14 (6) 498-509
    CrossrefPubMedSearch in Google Scholar
  • 6 Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL. 'Old' antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis 2012; 25 (6) 626-633
    CrossrefPubMedSearch in Google Scholar
  • 7 Bergen PJ, Landersdorfer CB, Zhang J , et al. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?. Diagn Microbiol Infect Dis 2012; 74 (3) 213-223
    CrossrefPubMedSearch in Google Scholar
  • 8 Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25 (1) 11-25
    CrossrefPubMedSearch in Google Scholar
  • 9 Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50 (6) 1953-1958
    CrossrefPubMedSearch in Google Scholar
  • 10 Barnett M, Bushby SR, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br Pharmacol Chemother 1964; 23: 552-574
    PubMedSearch in Google Scholar
  • 11 Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003; 47 (4) 1364-1370
    CrossrefPubMedSearch in Google Scholar
  • 12 Dudhani RV, Nation RL, Li J. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J Antimicrob Chemother 2010; 65 (7) 1412-1415
    CrossrefPubMedSearch in Google Scholar
  • 13 Nation RL, Li J, Cars O , et al. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis 2014; 58 (1) 139-141
    CrossrefPubMedSearch in Google Scholar
  • 14 Institute for Safe Medication Practices (ISMP). National alert issued: Dosing confusion with colistimethate for injection, 2011. Available at: http://www.ismp.org/pressroom/PR20110629.pdf . Accessed 24 August, 2014
    PubMed
  • 15 Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66 (9) 2070-2074
    CrossrefPubMedSearch in Google Scholar
  • 16 Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012; 73 (4) 354-360
    CrossrefPubMedSearch in Google Scholar
  • 17 Hawser SP. Susceptibility of Klebsiella pneumoniae clinical isolates from 2007 to 2009 to colistin and comparator antibiotics. Int J Antimicrob Agents 2010; 36 (4) 383-384
    CrossrefPubMedSearch in Google Scholar
  • 18 Nakamura T, Komatsu M, Yamasaki K , et al. Susceptibility of various oral antibacterial agents against extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae. J Infect Chemother 2014; 20 (1) 48-51
    CrossrefPubMedSearch in Google Scholar
  • 19 The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0 2014. Available at: http://www.eucast.org . Accessed 24 August, 2014
    PubMed
  • 20 Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. 2013
    PubMedSearch in Google Scholar
  • 21 Velkov T, Thompson PE, Nation RL, Li J. Structure–activity relationships of polymyxin antibiotics. J Med Chem 2010; 53 (5) 1898-1916
    CrossrefPubMedSearch in Google Scholar
  • 22 Hancock RE. Alterations in outer membrane permeability. Annu Rev Microbiol 1984; 38: 237-264
    CrossrefPubMedSearch in Google Scholar
  • 23 Moffatt JH, Harper M, Harrison P , et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010; 54 (12) 4971-4977
    CrossrefPubMedSearch in Google Scholar
  • 24 Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45 (3) 781-785
    CrossrefPubMedSearch in Google Scholar
  • 25 Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008; 61 (3) 636-642
    CrossrefPubMedSearch in Google Scholar
  • 26 Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 2010; 54 (9) 3783-3789
    CrossrefPubMedSearch in Google Scholar
  • 27 Bergen PJ, Tsuji BT, Bulitta JB , et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011; 55 (12) 5685-5695
    CrossrefPubMedSearch in Google Scholar
  • 28 Lora-Tamayo J, Murillo O, Bergen PJ , et al. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. J Antimicrob Chemother 2014; 69 (9) 2434-2442
    CrossrefPubMedSearch in Google Scholar
  • 29 Poudyal A, Howden BP, Bell JM , et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62 (6) 1311-1318
    CrossrefPubMedSearch in Google Scholar
  • 30 Deris ZZ, Yu HH, Davis K , et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2012; 56 (10) 5103-5112
    CrossrefPubMedSearch in Google Scholar
  • 31 Li J, Rayner CR, Nation RL , et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50 (9) 2946-2950
    CrossrefPubMedSearch in Google Scholar
  • 32 Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007; 51 (9) 3413-3415
    CrossrefPubMedSearch in Google Scholar
  • 33 Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 59 (3) 473-477
    CrossrefPubMedSearch in Google Scholar
  • 34 Lee HJ, Bergen PJ, Bulitta JB , et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013; 57 (8) 3738-3745
    CrossrefPubMedSearch in Google Scholar
  • 35 Bulitta JB, Yang JC, Yohonn L , et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 2010; 54 (5) 2051-2062
    CrossrefPubMedSearch in Google Scholar
  • 36 Forrest A, Silveira FP, Thamlikitkul V , et al. Risk factors for colistin-associated nephrotoxicity. In: Proceedings of the 1st International Conference on Polymyxins; May 2–4, 2013; Prato, Italy
    PubMed
  • 37 Sorlí L, Luque S, Grau S , et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 2013; 13: 380
    CrossrefPubMedSearch in Google Scholar
  • 38 Dudhani RV, Turnidge JD, Coulthard K , et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010; 54 (3) 1117-1124
    CrossrefPubMedSearch in Google Scholar
  • 39 Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010; 65 (9) 1984-1990
    CrossrefPubMedSearch in Google Scholar
  • 40 Bergen PJ, Forrest A, Bulitta JB , et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 2011; 55 (11) 5134-5142
    CrossrefPubMedSearch in Google Scholar
  • 41 Clancy CJ, Chen L, Hong JH , et al. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother 2013; 57 (11) 5258-5265
    CrossrefPubMedSearch in Google Scholar
  • 42 Zusman O, Avni T, Leibovici L , et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 2013; 57 (10) 5104-5111
    CrossrefPubMedSearch in Google Scholar
  • 43 Paul M, Carmeli Y, Durante-Mangoni E , et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014; 69 (9) 2305-2309
    CrossrefPubMedSearch in Google Scholar
  • 44 Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47 (5) 1766-1770
    CrossrefPubMedSearch in Google Scholar
  • 45 Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53 (5) 837-840
    CrossrefPubMedSearch in Google Scholar
  • 46 Marchand S, Lamarche I, Gobin P, Couet W. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J Antimicrob Chemother 2010; 65 (8) 1753-1758
    CrossrefPubMedSearch in Google Scholar
  • 47 Li J, Coulthard K, Milne R , et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52 (6) 987-992
    CrossrefPubMedSearch in Google Scholar
  • 48 Plachouras D, Karvanen M, Friberg LE , et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53 (8) 3430-3436
    CrossrefPubMedSearch in Google Scholar
  • 49 Couet W, Grégoire N, Gobin P , et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011; 89 (6) 875-879
    CrossrefPubMedSearch in Google Scholar
  • 50 Garonzik SM, Li J, Thamlikitkul V , et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55 (7) 3284-3294
    CrossrefPubMedSearch in Google Scholar
  • 51 Theuretzbacher U. Product information for parenteral colistin varies substantially across Europe. J Antimicrob Chemother 2014; 69 (7) 1987-1992
    CrossrefPubMedSearch in Google Scholar
  • 52 Nation RL, Velkov T, Li J. Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?. Clin Infect Dis 2014;
    PubMedSearch in Google Scholar
  • 53 Antachopoulos C, Karvanen M, Iosifidis E , et al. Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob Agents Chemother 2010; 54 (9) 3985-3987
    CrossrefPubMedSearch in Google Scholar
  • 54 Li J, Rayner CR, Nation RL , et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005; 49 (11) 4814-4815
    CrossrefPubMedSearch in Google Scholar
  • 55 Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41 (8) 1159-1166
    CrossrefPubMedSearch in Google Scholar
  • 56 Markou N, Markantonis SL, Dimitrakis E , et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30 (1) 143-151
    CrossrefPubMedSearch in Google Scholar
  • 57 Imberti R, Cusato M, Villani P , et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 2010; 138 (6) 1333-1339
    CrossrefPubMedSearch in Google Scholar
  • 58 Mohamed AF, Karaiskos I, Plachouras D , et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56 (8) 4241-4249
    CrossrefPubMedSearch in Google Scholar
  • 59 Kumar A, Roberts D, Wood KE , et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34 (6) 1589-1596
    CrossrefPubMedSearch in Google Scholar
  • 60 Luna CM, Aruj P, Niederman MS , et al; Grupo Argentino de Estudio de la Neumonía Asociada al Respirador group. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006; 27 (1) 158-164
    CrossrefPubMedSearch in Google Scholar
  • 61 Karvanen M, Plachouras D, Friberg LE , et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2013; 57 (1) 668-671
    CrossrefPubMedSearch in Google Scholar
  • 62 Luque S, Sorli L, Li J , et al. Effective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa. J Chemother 2014; 26 (2) 122-124
    CrossrefPubMedSearch in Google Scholar
  • 63 Markou N, Fousteri M, Markantonis SL , et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 2012; 67 (10) 2459-2462
    CrossrefPubMedSearch in Google Scholar
  • 64 Marchand S, Frat JP, Petitpas F , et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 2010; 65 (8) 1836-1837
    CrossrefPubMedSearch in Google Scholar
  • 65 Strunk AK, Schmidt JJ, Baroke E , et al. Single- and multiple-dose pharmacokinetics and total removal of colistin in a patient with acute kidney injury undergoing extended daily dialysis. J Antimicrob Chemother 2014; 69 (7) 2008-2010
    CrossrefPubMedSearch in Google Scholar
  • 66 Leporati M, Bua RO, Mariano F , et al. Determination by LC-MS/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration. Ther Drug Monit 2014; 36 (2) 182-191
    CrossrefPubMedSearch in Google Scholar
  • 67 Mohamed AF, Cars O, Friberg LE. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. J Antimicrob Chemother 2014; 69 (5) 1350-1361
    CrossrefPubMedSearch in Google Scholar
  • 68 Markantonis SL, Markou N, Fousteri M , et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009; 53 (11) 4907-4910
    CrossrefPubMedSearch in Google Scholar
  • 69 Ziaka M, Markantonis SL, Fousteri M , et al. Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. Antimicrob Agents Chemother 2013; 57 (4) 1938-1940
    CrossrefPubMedSearch in Google Scholar
  • 70 W S Yapa S, Li J, Patel K. , et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 2014; 58 (5) 2570-2579
    CrossrefPubMedSearch in Google Scholar
  • 71 Athanassa ZE, Markantonis SL, Fousteri MZ , et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 2012; 38 (11) 1779-1786
    CrossrefPubMedSearch in Google Scholar
  • 72 Bargiacchi O, Rossati A, Car P , et al. Intrathecal/intraventricular colistin in external ventricular device-related infections by multi-drug resistant Gram negative bacteria: case reports and review. Infection 2014; 42 (5) 801-809
    CrossrefPubMedSearch in Google Scholar
  • 73 Imberti R, Cusato M, Accetta G , et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. Antimicrob Agents Chemother 2012; 56 (8) 4416-4421
    CrossrefPubMedSearch in Google Scholar
  • 74 Karaiskos I, Galani L, Baziaka F, Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents 2013; 41 (6) 499-508
    CrossrefPubMedSearch in Google Scholar
  • 75 Karaiskos I, Galani L, Baziaka F , et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis with intraventricular colistin after application of a loading dose: a case series. Int J Antimicrob Agents 2013; 41 (5) 480-483
    CrossrefPubMedSearch in Google Scholar